Nasdaq stocks posting largest percentage decreases
AP - Thu Apr 17, 5:02PM CDT
NEW YORK (AP) — A look at the 10 biggest percentage decliners on Nasdaq at the close of trading:
Today's Dead Cat Bounce Stock Is Tekmira Pharmaceuticals Corporation (TKMR)
at The Street - Wed Apr 16, 8:45AM CDT
Trade-Ideas LLC identified Tekmira Pharmaceuticals Corporation (TKMR) as a "dead cat bounce" (down big yesterday but up big today) candidate
Why Tekmira Pharmaceuticals (TKMR) Stock Is Down Today
at The Street - Mon Apr 14, 2:07PM CDT
Tekmira Pharmaceuticals (TKMR) plunged Monday amid reports that Novartis (NVS) is closing a significant portion of its RNAi research endeavors in Boston. FierceBiotech reported the pharmaceutical giant's confirmation that ongoing problems in...
How Did You File and Do You Owe? - Real Time Insight
Brian Bolan - Zacks Investment Research - Mon Apr 14, 1:39PM CDT
Death is a certainty, taxes, well I have some questions there.
Research and Markets: Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
Business Wire - Mon Apr 14, 12:42PM CDT
Research and Markets (http://www.researchandmarkets.com/research/pcldxf/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering.
Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating
M2 - Mon Apr 14, 11:27AM CDT
Research and Markets (http://www.researchandmarkets.com/research/6dhrqp/global_rnai_drug) has announced the addition of the "Global RNAi Drug Delivery Market 2014-2018 with Alnylam Pharmaceuticals, Isis Pharmaceuticals.,Merck & Co & Tekmira Pharmaceuticals Dominating" report to their offering. The Global RNAi Drug Delivery market to grow at a CAGR of 21% to 2018. According to the report, one of the major drivers in this market is the increase in RNA therapeutic development. Therapeutic benefits greatly depend on the efficiency of the RNA delivery to specific diseased cells. This factor is the key to the development of RNAi drug delivery technologies and the market associated with it. Major advances in RNAi drug delivery are aimed at developing better delivery agents with excellent efficacy and the ability to target specific cells. For example, Bio-Path Holdings Inc. developed systemic delivery of antisense, small interfering RNA, and hydrophobic small molecules for treatment of various diseases using its neutral lipid drug delivery technology (neutral liposome). Similarly, Inovio's skin electroporation technology was used for the successful delivery of small interfering RNA molecules to skin in animal studies. Thus, technological innovations would further contribute to the growth of the Global RNAi Drug Delivery market. Further, the report states that one of the major challenges in this market is the targeted delivery of RNA therapeutic molecules. During in vivo drug testing procedures, many companies engaged in developing RNA therapeutics found it difficult to deliver the RNA molecules to specific tissues to bring about a therapeutic effect. Key vendors dominating this space are: - Alnylam Pharmaceuticals Inc. - Isis Pharmaceuticals, Inc - Merck & Co. Inc. - Tekmira Pharmaceuticals Corp.. Key Topics Covered: 01. Executive Summary 02. List of Abbreviations 03. Scope of the Report 04. Market Research Methodology 05. Introduction 06. Market Landscape 07. Market Segmentation 08. Geographical Segmentation 09. Buying Criteria 10. Market Growth Drivers 11. Drivers and their Impact 12. Market Challenges 13. Impact of Drivers and Challenges 14. Market Trends 15. Trends and their Impact 16. Vendor Landscape 17. Key Vendor Analysis For more information visit http://www.researchandmarkets.com/research/6d..._rnai_drug
Global Neuroendocrine Cancer Clinical Trials Review, H1, 2014
M2 - Wed Apr 09, 3:53AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mssxcd/neuroendocrine) has announced the addition of the "Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" report to their offering. Neuroendocrine Cancer Global Clinical Trials Review, H1, 2014" provides data on the Neuroendocrine Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Neuroendocrine Cancer. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Neuroendocrine Cancer. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each, along with the clinical trial scenario in BRIC nations - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Clinical Trial Overview of Top Companies/Institutions - Novartis AG - Pfizer Inc. - Ipsen S.A. - F. Hoffmann-La Roche Ltd. - Progenics Pharmaceuticals, Inc. - Tekmira Pharmaceuticals Corp. - Threshold Pharmaceuticals, Inc. - Merck & Co., Inc. - Eli Lilly and Company - Daiichi Sankyo Company, Limited - National Cancer Institute - The University of Texas M. D. Anderson Cancer Center - Memorial Sloan Kettering Cancer Center - Stanford University - Grupo Espanol de Tumores Neuroendocrinos - University of Wisconsin Madison - The University of Iowa - University of California, San Francisco - Alberta Health Services Visit http://www.researchandmarkets.com/research/ms...oendocrine
Tekmira Presents Advances in Anti-Viral Product Platform at Scientific Symposium
GlobeNewswire - Tue Apr 01, 9:25AM CDT
Tekmira Pharmaceuticals Corporation (Nasdaq:TKMR) (TSX:TKM), a leading developer of RNA interference (RNAi) therapeutics, announced that recent advances in its anti-viral product platform were presented at the 6th International Symposium of Filoviruses, which is taking place in Galveston, Texas from March 30 to April 2, 2014.
Global RNA Interference (RNAi) Therapy Market Outlook 2018
M2 - Tue Apr 01, 6:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/hthtnb/global_rna) has announced the addition of the "Global RNA Interference (RNAi) Therapy Market Outlook 2018" report to their offering. The popularity of RNAi technology has been increasing in recent times as is has become a major component of basic research, and in drug discovery. Over the years this technology has become an integral part of the process of determining the functions of gene, in analyzing pathways, and in the validation of the target both in academia and in industry. Since discovery, RNA interference is considered to be a turning point for molecular biology, it is most likely that this technology would grow in terms of its popularity and the significant research activity would be recorded in order to develop efficient and safe drug delivery mechanisms based on the RNAi therapy. Being a powerful tool for the study of functional genomics, this therapy provides enables the scientist to successfully silence any gene with artificial triggers of RNAi and utilizing the cellular machinery for efficient targeting of complementary transcripts. There are specific strategic reasons for the pharmaceutical industry to take interest in developing RNAi-based therapeutics. With the existing product pipelines exhausting for the big pharma companies, they are currently looking into RNAi therapeutics as potential fields which would enable the pipelines to be filled. Additionally, these companies have identified RNAi therapeutics to have the capability to target those diseases which are considered to be undruggable by small-molecule compounds or biologics. Thus, by investing in RNAi therapeutics at an early stage, the pharma companies would be able to build a strong foothold and have a commanding position in the market once these RNAi-based drugs reached the market. The RNAi therapy market, in the future years is likely to witness an increased level of activity in terms of RNAI technology development, specifically in the space of drug delivery. Though the main concept and clinical results behind RNAi are compelling, the pharma companies are still working towards identifying some new ideas which have great opportunity to grow. With human proof of concept demonstrated, it is most likely that the RNAi companies would reformulate new delivery technology and enjoy the benefits. Global RNAi Therapy Report Findings: - Number of RNAi Based Drugs in Clinical Trials: 151 - Highest RNAi Clinical Trial in Preclinical Phase - Oncology Dominating the RNAi Based Drugs Clinical Trial Process - US Dominates RNAi Market & Clinical Trial Landscape Key Topics Covered: 1. Introduction to RNA Interference (RNAi) Therapy 2. Benefits of RNA Interference (RNAi) Therapy 3. RNA Interference (RNAi) Drug Delivery Mechanics 4. Global RNA Interference (RNAi) Therapy Market Overview 5. Global RNA Interference (RNAi) Market Dynamics 6. RNAi Clinical Pipeline by Phase, Indication & Country 7. Suspended & Discontinued RNAi Profiles 8. Competitive Landscape Companies Mentioned - Arrowhead Research - Alnylam Pharmaceuticals - Benitec Biopharma - Dicerna Pharmaceuticals - InteRNA Technologies - Isis Pharmaceuticals - RXi Pharmaceuticals - Santaris Pharma - Silence Therapeutics - Tekmira Pharmaceuticals Corporation For more information visit http://www.researchandmarkets.com/research/hthtnb/global_rna